EA201892605A1 - METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR - Google Patents
METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITORInfo
- Publication number
- EA201892605A1 EA201892605A1 EA201892605A EA201892605A EA201892605A1 EA 201892605 A1 EA201892605 A1 EA 201892605A1 EA 201892605 A EA201892605 A EA 201892605A EA 201892605 A EA201892605 A EA 201892605A EA 201892605 A1 EA201892605 A1 EA 201892605A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- skin cancer
- inhibitor
- administration
- treating skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к способам лечения, снижения тяжести или ингибирования роста злокачественной опухоли (например, рака кожи). Способы по настоящему документу включают введение пациенту терапевтически эффективного количества антагониста белка программируемой клеточной гибели 1 (PD-1) (например, антитела против PD-1). В определенных вариантах осуществления рак кожи представляет собой плоскоклеточную карциному кожи или базальноклеточную карциному.The present invention relates to methods for treating, reducing, or inhibiting the growth of a malignant tumor (for example, skin cancer). The methods of this document include administering to a patient a therapeutically effective amount of a programmable cell death protein 1 (PD-1) antagonist (eg, antibodies against PD-1). In certain embodiments, skin cancer is squamous cell carcinoma of the skin or basal cell carcinoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762451274P | 2017-01-27 | 2017-01-27 | |
PCT/US2017/032408 WO2017197263A1 (en) | 2016-05-13 | 2017-05-12 | Methods of treating skin cancer by administering a pd-1 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892605A1 true EA201892605A1 (en) | 2019-04-30 |
Family
ID=66436975
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892605A EA201892605A1 (en) | 2017-01-27 | 2017-05-12 | METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR |
EA201892604A EA201892604A1 (en) | 2017-01-27 | 2017-05-12 | COMBINATION OF ANTIBODIES AGAINST PD-1 AND IRRADIATION FOR THE TREATMENT OF MALIGNANT TUMOR |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892604A EA201892604A1 (en) | 2017-01-27 | 2017-05-12 | COMBINATION OF ANTIBODIES AGAINST PD-1 AND IRRADIATION FOR THE TREATMENT OF MALIGNANT TUMOR |
Country Status (1)
Country | Link |
---|---|
EA (2) | EA201892605A1 (en) |
-
2017
- 2017-05-12 EA EA201892605A patent/EA201892605A1/en unknown
- 2017-05-12 EA EA201892604A patent/EA201892604A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201892604A1 (en) | 2019-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001120A (en) | Methods of treating skin cancer by administering a pd-1 inhibitor. | |
EA201991214A1 (en) | ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION | |
ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
PH12018500642A1 (en) | Anti-garp antibody | |
EA201891268A1 (en) | COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS | |
PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
BR112016029916A2 (en) | mnk inhibitors and related methods | |
MX2019007243A (en) | Ectonucleotidase inhibitors and methods of use thereof. | |
PH12021551126A1 (en) | Humanized antibodies against c-kit | |
IN2015KN00350A (en) | ||
MX2024000780A (en) | Anti-pd-1 antibodies for treatment of lung cancer. | |
MX2022013390A (en) | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor. | |
EA201892541A1 (en) | HUMANIZED ANTI-IL-1R3 ANTIBODIES | |
PE20200602A1 (en) | MACROCICLIC COMPOUND AND ITS USES | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
EP4382168A3 (en) | Intralesional administration of pd-1 inhibitors for treating skin cancer | |
PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
BR112016023011A2 (en) | gastric cancer treatment | |
MX2020012782A (en) | Ccr5 inhibitor for use in treating cancer. | |
BR112018011196A2 (en) | use pyrimidine pyrimidazinones to treat cancer | |
PH12016000355B1 (en) | Use of xanthophylls for the treatment of cancers | |
EA201892605A1 (en) | METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR | |
EA202092481A1 (en) | COMBINED TREATMENT WITH CD73 ANTAGONIST AND PD-1 / PD-L1 AXIS ANTAGONIST | |
MX2021015922A (en) | Stabilized chimeric synthetic proteins and therapeutic uses thereof. |